Tyenne

Tyenne® (tocilizumab-aazg) is an injectable interleukin-6 (IL-6) receptor antagonist that may be used to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Tyenne® works by targeting and binding to a protein that is associated with inflammation called interleukin-6 (IL-6), inhibiting signaling through both soluble and membrane-bound IL-6 receptors. This proinflammatory cytokine is produced by a variety of immune system cells including T- and B-cells, lymphocytes, monocytes, and fibroblasts. It is also locally produced by synovial and endothelial cells in joints, contributing to inflammatory conditions such as rheumatoid arthritis.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

Tyenne® Referral Form